India Contract Manufacturing Organization (CMO) - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The india contract manufacturing organization market size was valued at USD 25.81 billion in 2025 and estimated to grow from USD 29.53 billion in 2026 to reach USD 57.94 billion by 2031, at a CAGR of 14.43% during the forecast period (2026-2031). This report is Segmented by Service Type (API and Intermediates, Finished Dose), Molecule Type (Small Molecules, and Large Molecules/Biologics), End-User (Big Pharma, Mid-Size Pharma, and Virtual/Start-ups), Therapeutic Area (Oncology, Cardiovascular, and More), and Manufacturing Scale (Pre-Clinical, Clinical, Commercial). The Market Forecasts are Provided in Terms of Value (USD).

India Contract Manufacturing Organization (CMO) Market Trends and Insights

Growing Biologics Outsourcing Pipeline

India is securing a rising share of global biologics contracts as sponsors pursue lower cost locations without compromising quality. Aurigene opened a 70,000-square-foot monoclonal antibody plant in Genome Valley in 2025, illustrating the industry’s pivot toward mammalian cell culture expertise. Specialized facilities command premium pricing because barriers to entry remain high, yet India still undercuts Western cost structures. CDSCO Schedule M upgrades ensure alignment with U.S. FDA and EMA standards, removing a key procurement hurdle for multinational firms. As a result, contract values for biologics projects are lengthening, and repeat orders are climbing. Sustained double-digit growth is therefore expected for this capability set through 2030.

Strong Demand for Complex Injectables

Sterile manufacturing complexity and limited global capacity are funneling injectable assignments toward Indian CDMOs. Sanofi’s USD 437 million Hyderabad expansion focuses on pre-filled syringes and lyophilized oncology products, underscoring confidence in local expertise. Domestic players are simultaneously scaling fermentation suites for high-potency intermediates. Premium pricing persists because safety regulations mandate rigorous environmental controls, while lead times from alternate Asian hubs remain long. The segment meshes with global moves toward personalized medicine, where complex delivery systems are essential. These conditions maintain a high-margin outlook over the next two years.

Volatile Raw-Material Prices Linked to China Supply

China supplies more than 70% of India’s key starting materials, and 2024 environmental clampdowns raised intermediate costs by 20-30%. Margin compression forces CDMOs to renegotiate long-term contracts, straining client relationships. Although PLI parks promise domestic feedstock, scale-up will take multiple years. Hedging strategies and dual sourcing add overheads, weighing on near-term profitability. Sponsors may also withhold multi-year awards until price visibility improves.

Other drivers and restraints analyzed in the detailed report include:

• Capacity Expansions by Global Big-Pharma in India
• AI-Enabled Process-Development Efficiencies
• Rising FDA Warning Letters to Indian Sites

List of Companies Covered in this Report:

• Divi’s Laboratories Limited
• Dr. Reddy’s Laboratories Limited
• Sun Pharmaceutical Industries Limited
• Aurobindo Pharma Limited
• Zydus Lifesciences Limited (Cadila Healthcare)
• Cipla Limited
• Lupin Limited
• Jubilant Pharmova Limited
• Biocon Limited
• MSN Laboratories Private Limited
• Viatris Inc. (Mylan Laboratories Ltd.)
• Akums Drugs and Pharmaceuticals Limited
• Wockhardt Limited
• Theon Pharmaceuticals Limited
• BDR Pharmaceuticals International Private Limited
• Ciron Drugs & Pharmaceuticals Private Limited
• Medipaams India Private Limited
• Bharat Biotech International Limited
• Strides Pharma Science Limited
• Alkem Laboratories Limited

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support